Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London.
A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company develops transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel Prize-winning science of RNAi, achieving critical breakthroughs and bringing six medicines to approval. Its medicines are available in more than 70 countries, supported by a robust and rapidly expanding pipeline, and the Company is consistently recognized as an exceptional workplace and a socially responsible organization. Alnylam is executing its Alnylam 2030 strategy to accelerate innovation and scale its impact on human health. For more information, visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.
Alnylam Pharmaceuticals, Inc.
Bo Piela
(Media)
508-308-9783
Josh Brodsky
(Investors)
617-551-8276
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104554718/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
It’s Been a Long Time Since Bonds Looked This Good
United States